Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Theravance Biopharma Q3 2023 GAAP EPS $(0.17) Beats $(0.21) Estimate, Sales $15.69M Beat $15.00M Estimate

Author: Benzinga Newsdesk | November 07, 2023 06:03pm
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $15.69 million which beat the analyst consensus estimate of $15.00 million by 4.62 percent. This is a 26.04 percent increase over sales of $12.45 million the same period last year.

Posted In: TBPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist